Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and biopharmaceutical company Pfizer Inc (NYSE:PFE) on Tuesday announced positive data from a Phase 2 study of their Lyme disease vaccine candidate, VLA15.

The study evaluated the immune response and safety profile after a second booster dose.

Results showed a strong immune response and favourable safety profile in all age groups. Seroconversion rates were high, indicating effective protection against Lyme disease.

VLA15 is currently in Phase 3 clinical trials and could potentially be approved in 2026.